Jennerex publishes proof-of-concept data for oncolytic virus therapy
This article was originally published in Scrip
Executive Summary
As privately-owned Jennerex published positive results from a proof-of-concept study evaluating its oncolytic therapy, JX-594 (also TG6006), in patients with metastatic melanoma, the company reiterated previously announced plans to begin a Phase IIb trial of the product in advanced liver cancer in Q3 of year.